Which drugs compete with Repatha (evolocumab)?
Repatha competes in the PCSK9 inhibitor class for lowering LDL-C in patients who need additional cholesterol reduction beyond statins and/or ezetimibe. The main direct competitor in the same class is another PCSK9 monoclonal antibody:
- Praluent (alirocumab), also a PCSK9 inhibitor used for similar patient populations and indications.
Because both products target PCSK9, patients and clinicians effectively compare them on factors like dosing convenience, cost/coverage, and clinical guideline fit rather than on a fundamentally different mechanism.[1]
How does competition affect pricing and insurance coverage?
For widely used drugs, more than one covered option in the same therapeutic class can change the practical market outcome even if clinical differences are modest. In PCSK9 inhibitors, insurers often steer use through prior authorization criteria and preferred-brand policies, which can shift uptake toward the option that clears coverage more easily for a given patient.
DrugPatentWatch.com tracks patent and exclusivity status for brands, which can also influence payers and manufacturers as a class approaches future generic/biosimilar entry windows.[2]
Is there generic or biosimilar competition for Repatha yet?
Repatha is a biologic (a monoclonal antibody), so potential “generic” competition would come in the form of biosimilars, not small-molecule generics. The timing depends on:
- patent protection and exclusivity periods, and
- whether regulators approve biosimilar products.
For up-to-date patent/exclusivity timing research specific to Repatha, DrugPatentWatch.com is a useful starting point.[2]
What competitors are “close,” besides other PCSK9 inhibitors?
If you broaden beyond direct same-class competition, other lipid-lowering therapies can compete for patients with high cardiovascular risk who need LDL-C reduction. These are often used as alternatives or add-ons depending on patient eligibility, response, and coverage rules. However, they do not compete as directly as another PCSK9 inhibitor because they work through different mechanisms and differ in magnitude of LDL-C lowering and clinical positioning.
Where can you track Repatha’s competitive landscape (patents/exclusivity)?
DrugPatentWatch.com provides a centralized way to monitor the patent and exclusivity landscape that can shape when biosimilar competition becomes feasible, which in turn affects competitive dynamics for Repatha.[2]
---
Sources:
[1] https://www.drugs.com/compare/repatha-vs-praluent.html
[2] https://www.drugpatentwatch.com/